MA51873A - Molécules probiotiques pour réduire la virulence d'agents pathogènes - Google Patents

Molécules probiotiques pour réduire la virulence d'agents pathogènes

Info

Publication number
MA51873A
MA51873A MA051873A MA51873A MA51873A MA 51873 A MA51873 A MA 51873A MA 051873 A MA051873 A MA 051873A MA 51873 A MA51873 A MA 51873A MA 51873 A MA51873 A MA 51873A
Authority
MA
Morocco
Prior art keywords
virulence
reduce
pathogenic agents
probiotic molecules
probiotic
Prior art date
Application number
MA051873A
Other languages
English (en)
Inventor
Monica Angela Cella
Sarah M Curtis
Jonathon Patrick Roepke
Original Assignee
Microsintesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microsintesis Inc filed Critical Microsintesis Inc
Publication of MA51873A publication Critical patent/MA51873A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/195Proteins from microorganisms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/46Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1021Tetrapeptides with the first amino acid being acidic
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25Peptides having up to 20 amino acids in a defined sequence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
MA051873A 2017-03-16 2018-03-16 Molécules probiotiques pour réduire la virulence d'agents pathogènes MA51873A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762472061P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
MA51873A true MA51873A (fr) 2020-01-22

Family

ID=63521745

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051873A MA51873A (fr) 2017-03-16 2018-03-16 Molécules probiotiques pour réduire la virulence d'agents pathogènes

Country Status (16)

Country Link
US (2) US11912788B2 (fr)
EP (1) EP3595698A4 (fr)
JP (2) JP2020510096A (fr)
KR (2) KR20240046640A (fr)
CN (1) CN110621332A (fr)
AU (2) AU2018233183A1 (fr)
BR (1) BR112019019256A2 (fr)
CA (1) CA3056719A1 (fr)
CL (1) CL2019002640A1 (fr)
EA (1) EA201992176A1 (fr)
MA (1) MA51873A (fr)
MX (1) MX2019011058A (fr)
PE (1) PE20191783A1 (fr)
PH (1) PH12019502340A1 (fr)
SG (1) SG11201909606RA (fr)
WO (1) WO2018165765A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510096A (ja) 2017-03-16 2020-04-02 マイクロシンテシス インコーポレイテッド 病原体の毒性を低減するためのプロバイオティクス分子
BR112019019255A2 (pt) * 2017-03-16 2020-04-14 Microsintesis Inc composições e métodos envolvendo moléculas probióticas
CN114786703A (zh) * 2019-07-02 2022-07-22 微合成有限公司 群体感应抑制剂和/或后生元代谢物及相关方法
CN115039885B (zh) * 2021-05-14 2023-11-03 江苏艾兰得营养品有限公司 一种具有抑制奇异变形杆菌生长作用的副干酪乳杆菌及其益生菌组合物、发酵液和应用
GB2613406A (en) * 2021-05-14 2023-06-07 Ivc Nutrition Corp Probiotic having effect of inhibiting growth of proteus mirabilis, and fermentation broth and use thereof
KR102337951B1 (ko) * 2021-06-25 2021-12-13 주식회사 비피도 요로감염 개선, 예방 또는 치료를 위한 락토바실러스 헬베티쿠스 gut10 균주 및 이를 포함하는 조성물
KR102356423B1 (ko) * 2021-07-02 2022-02-09 (주)에스디생명공학 항균, 피부 보습, 항아토피, 피부 장벽 강화, 및 주름 개선 활성을 갖는 복합 균주를 유효성분으로 포함하는 조성물
KR102618322B1 (ko) * 2021-10-08 2023-12-27 순천향대학교 산학협력단 신규한 락토 바실러스 균주, 및 이를 포함하는 결핵 예방, 치료, 또는 개선용 조성물
CN114106096A (zh) * 2021-11-16 2022-03-01 华南理工大学 一种具有改善睡眠活性的六肽及其应用
CN114591879B (zh) * 2022-05-11 2022-12-06 中国农业大学 一种抑制幽门螺杆菌的发酵乳杆菌及其应用
KR102551065B1 (ko) * 2022-05-12 2023-07-03 중앙대학교 산학협력단 김치로부터 유래된 LAB(lactic acid bacteria)을 유효성분으로 포함하는 항-바이오필름 조성물
CN116478882A (zh) * 2023-05-05 2023-07-25 石河子大学 能够提高绵羊日增重和饲料转化率的产酸的混合菌制剂的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395309B1 (fr) 1989-04-28 1995-12-27 Takara Shuzo Co. Ltd. Polypeptide semblable à la calpastatine humaine
FR2686085B1 (fr) 1992-01-10 1995-08-04 Agronomique Inst Nat Rech Peptides representant des fragments du cmp, anticorps diriges contre lesdits peptides, et leurs utilisations.
WO1994018832A1 (fr) 1993-02-26 1994-09-01 Dana-Farber Cancer Institute, Inc. Modulation a mediation cd4 de kinases lipidiques
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
WO2004092206A1 (fr) * 2003-04-14 2004-10-28 Meiji Dairies Corporation Peptide, immunopotentiateur et nourriture fonctionnelle ; procede de fabrication de la nourriture fonctionnelle
DE10317870A1 (de) * 2003-04-17 2004-11-04 Crompton Vinyl Additives Gmbh Neues Stabilisatorsystem zur Stabilisierung von halogenhaltigen Polymeren
EP1706126A4 (fr) * 2003-12-04 2009-07-01 Biofilms Strategies Inc Procedes et compositions pour la prevention de formation de biofilms, la reduction de biofilms existants, et pour la reduction des populations de bacteries
US7306677B2 (en) * 2004-01-30 2007-12-11 Boston Scientific Corporation Clamping fixture for coating stents, system using the fixture, and method of using the fixture
JP5068174B2 (ja) 2004-12-23 2012-11-07 カンピナ ネーデルランド ホールディング ビー.ブイ. Dpp−ivを阻害するペプチド中に濃縮されたタンパク質の加水分解物及びその使用
WO2007057872A2 (fr) 2005-11-21 2007-05-24 Teagasc-National Diary Products Research Centre Peptides antimicrobiens et souches bactériennes les produisant
US8431528B2 (en) 2008-05-16 2013-04-30 University Of Maryland, Baltimore Antibacterial Lactobacillus GG peptides and methods of use
US20110262400A1 (en) * 2008-06-27 2011-10-27 University Of Guelph Probiotic bacterial molecules and their use in methods to treat/prevent infection by harmful bacteria and to provide nutritional health
EP2550529B1 (fr) 2010-03-23 2021-11-17 Iogenetics, LLC. Procédés bioinformatiques pour déterminer la liaison de peptides
PT105073A (pt) 2010-04-26 2011-10-26 Consejo Superior Investigacion Processo de obtenção de extractos peptídicos bioactivos através da hidrólise de proteínas de soro de leite com enzimas de cynara cardunculus, referidos extractos e respectivas utilizações
WO2014020209A1 (fr) * 2012-07-30 2014-02-06 Consejo Superior De Investigaciones Científicas (Csic) Utilisation d'hydrolysats de protéines lactées comme protecteurs au niveau gastro-intestinal
US9273096B2 (en) * 2012-08-29 2016-03-01 Agency For Science, Technology And Research Amphiphilic peptides comprising the formula I: (X1Y1X2Y2)n, and uses thereof
US9637523B2 (en) 2012-08-31 2017-05-02 Westfaelische Wilhelms-Universitaet Muenster Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease
US9861666B2 (en) 2013-08-12 2018-01-09 Mansel Griffiths Antiviral methods and compositions comprising probiotic bacterial molecules
ES2757563T3 (es) * 2013-10-31 2020-04-29 Hutchison Biofilm Medical Solutions Ltd Uso de péptidos en resistencia a antibióticos
CA3172682A1 (fr) 2015-04-23 2016-10-27 Nantomics, Llc Neo-epitopes de cance
JP2020510096A (ja) 2017-03-16 2020-04-02 マイクロシンテシス インコーポレイテッド 病原体の毒性を低減するためのプロバイオティクス分子
BR112019019255A2 (pt) 2017-03-16 2020-04-14 Microsintesis Inc composições e métodos envolvendo moléculas probióticas

Also Published As

Publication number Publication date
EP3595698A4 (fr) 2020-12-23
PH12019502340A1 (en) 2020-10-19
JP2023036938A (ja) 2023-03-14
US20200017547A1 (en) 2020-01-16
US20240150399A1 (en) 2024-05-09
JP2020510096A (ja) 2020-04-02
CA3056719A1 (fr) 2018-09-20
KR20190140443A (ko) 2019-12-19
WO2018165765A9 (fr) 2018-11-22
US11912788B2 (en) 2024-02-27
EP3595698A1 (fr) 2020-01-22
AU2022203650B2 (en) 2024-04-11
AU2018233183A1 (en) 2019-10-31
AU2022203650A1 (en) 2022-06-16
BR112019019256A2 (pt) 2020-04-14
PE20191783A1 (es) 2019-12-24
CN110621332A (zh) 2019-12-27
KR20240046640A (ko) 2024-04-09
SG11201909606RA (en) 2019-11-28
WO2018165765A1 (fr) 2018-09-20
MX2019011058A (es) 2019-12-09
EA201992176A1 (ru) 2020-03-04
CL2019002640A1 (es) 2020-05-15

Similar Documents

Publication Publication Date Title
MA51873A (fr) Molécules probiotiques pour réduire la virulence d'agents pathogènes
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA44486A (fr) Procédés d'intervention précoce pour prévenir ou atténuer la toxicité
ITUA20161821A1 (it) Sensori ultrasonici per misurare l'irregolarita' del terreno
FR24C1017I1 (fr) Utilisations d'antagonistes d'il-13 pour le traitement de la dermatite atopique
MA43811A (fr) Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA51795A (fr) Oligonucléotides pour moduler l'expression de tmem106b
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
MA46431A (fr) Composés et procédés pour réduire l'expression de tau
MA45327A (fr) Utilisation de probiotiques pour améliorer l'absorption des protéines
MA43051A (fr) Polythérapie pour le traitement d'une du vhc
MA50163A (fr) Compositions, utilisations et méthodes pour le traitement de l'infertilité et de la sous-fertilité
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
IT201700085409A1 (it) Composizione per il trattamento di infezioni causate da agenti patogeni
MA45492A (fr) Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
FR3023472B1 (fr) Ensemble pour l'arthroplastie du pied
TH188028B (th) กระเป๋า
TH184653B (th) ขวด
MA50120A (fr) Méthodes de traitement à l'aide d'un promédicament d'amphétamine
TH164464B (th) อ่างล้างหน้า